A clot-busting catheter cut early deterioration in serious pulmonary embolism

Pulmonary embolism is the third most common cause of cardiovascular death, and the treatment of it has barely changed in two decades [s2]. Where heart attack and stroke acquired catheter-based interventions and the systems to deliver them, pulmonary embolism largely did not.

PRAGUE-26, presented in a Hot Line session at ESC Congress 2026 on 31 August and published in the New England Journal of Medicine the same day, tested whether a straightforward catheter procedure changes the early course of the disease [s1] [s2].

What the trial did

At 11 sites in Czechia, patients with acute intermediate-high risk pulmonary embolism — a risk category defined by the 2019 ESC Guidelines — were randomised 1:1 to catheter-directed thrombolysis or to standard anticoagulation alone, using intravenous unfractionated heparin or subcutaneous low-molecular-weight heparin [s2].

Catheter-directed thrombolysis delivers a clot-dissolving drug through a catheter placed directly into the pulmonary artery, rather than infusing it into a vein and hoping enough reaches the clot. The investigators describe it as a simple and relatively inexpensive procedure performed in a catheterisation laboratory, and deliberately tested the conventional form of it, without ultrasound facilitation [s2].

The primary endpoint was a composite of all-cause mortality, pulmonary embolism recurrence, or cardiorespiratory decompensation or collapse, within seven days of randomisation [s2]. In total 558 patients were randomised, with a median age of 64 years, and 41% were women [s2].

What happened

The primary endpoint occurred in 0.7% of the catheter-directed thrombolysis group and 6.8% of the standard-care group, a relative risk of 0.10 (95% CI 0.02 to 0.44, p<0.001) [s2].

That difference was driven primarily by a lower rate of cardiorespiratory decompensation or collapse in the intervention arm [s2] — which is worth stating plainly, because it means the result is mostly about preventing acute deterioration rather than about preventing death within the first week.

On bleeding, there was no apparent difference within seven days: 4.6% in the catheter group against 5.0% with standard care (p=0.846) [s2]. There were two cases of intracranial bleeding in the catheter-directed thrombolysis group and none in the standard-care group [s2]. There were four deaths in the standard-care group within seven days and one death in the catheter group within 30 days [s2].

The investigators also reported early improvement in right ventricular strain on echocardiography in the intervention arm, which they describe as consistent with previous studies of the technique [s2].

How much weight the result can carry

The relative risk of 0.10 is arresting, and the confidence interval — 0.02 to 0.44 — excludes no effect by a wide margin [s2]. But three things temper it.

First, the composite. Cardiorespiratory decompensation or collapse is a clinically meaningful outcome, but it is a softer one than death, it was defined by prespecified criteria in the trial protocol [s2], and it is the component doing most of the work. A reader who takes "0.7% versus 6.8%" as a mortality result has misread it.

Second, the numbers behind the deaths. Four deaths in one arm within seven days and one in the other within 30 days are counts small enough that they cannot support a survival claim in either direction [s2].

Third, the intracranial bleeds. Two against none is not a statistically interpretable comparison, and the overall bleeding rates were similar [s2]. But intracranial haemorrhage is the specific harm that has constrained thrombolysis in pulmonary embolism for decades, and two events in the intervention arm against none in the control arm is the kind of imbalance that needs a larger denominator before anyone can call it reassuring.

The trial was open in design — a procedure cannot easily be blinded — and was conducted entirely within one national network, in tertiary centres already equipped to do the intervention [s2]. Whether the result reproduces in systems without that infrastructure is a separate question from whether the intervention works.

The study was funded by the Ministry of Health of the Czech Republic and Charles University [s2]. Its design and rationale were published in advance [s2].

What to watch

The investigators are explicit about the intended consequence. New ESC Guidelines on pulmonary embolism are due to be published next year, and PRAGUE-26's results are offered as input to them [s2].

The specific thing to watch is how a guideline committee handles a primary endpoint that is overwhelmingly composed of a non-fatal component, in a trial of 558 patients, with two intracranial bleeds in the treatment arm [s2]. A strong recommendation would be a notable act of extrapolation; a conditional one would be the more conventional reading of this evidence.

This article describes trial results. It is not advice about any treatment, and nothing here should be used to make decisions about care.

Sources

• Catheter-Directed Thrombolysis in Intermediate-High-Risk Pulmonary Embolism, New England Journal of Medicine, 31 August 2026
• Positive news for the treatment of pulmonary embolism, European Society of Cardiology, 31 August 2026